These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35773707)

  • 1. Potential association of bone mineral density loss with cognitive impairment and central and peripheral amyloid-β changes: a cross-sectional study.
    Zhang P; Zhou Y; Chen G; Li J; Wang B; Lu X
    BMC Musculoskelet Disord; 2022 Jun; 23(1):626. PubMed ID: 35773707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.
    van Steenoven I; van der Flier WM; Scheltens P; Teunissen CE; Lemstra AW
    Alzheimers Res Ther; 2019 Oct; 11(1):83. PubMed ID: 31601267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer's disease: a cross-sectional analysis from the SILCODE study.
    Sheng C; Yang K; He B; Du W; Cai Y; Han Y
    Alzheimers Res Ther; 2022 Feb; 14(1):35. PubMed ID: 35164860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood Derived Amyloid Biomarkers for Alzheimer's Disease Prevention.
    Udeh-Momoh C; Zheng B; Sandebring-Matton A; Novak G; Kivipelto M; Jönsson L; Middleton L
    J Prev Alzheimers Dis; 2022; 9(1):12-21. PubMed ID: 35098969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.
    Gleason CE; Norton D; Anderson ED; Wahoske M; Washington DT; Umucu E; Koscik RL; Dowling NM; Johnson SC; Carlsson CM; Asthana S;
    J Alzheimers Dis; 2018; 61(1):79-89. PubMed ID: 29125485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study.
    Pérez-Grijalba V; Arbizu J; Romero J; Prieto E; Pesini P; Sarasa L; Guillen F; Monleón I; San-José I; Martínez-Lage P; Munuera J; Hernández I; Buendía M; Sotolongo-Grau O; Alegret M; Ruiz A; Tárraga L; Boada M; Sarasa M;
    Alzheimers Res Ther; 2019 Dec; 11(1):96. PubMed ID: 31787105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease.
    Almeida RP; Schultz SA; Austin BP; Boots EA; Dowling NM; Gleason CE; Bendlin BB; Sager MA; Hermann BP; Zetterberg H; Carlsson CM; Johnson SC; Asthana S; Okonkwo OC
    JAMA Neurol; 2015 Jun; 72(6):699-706. PubMed ID: 25893879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between CSF Aβ42 and amyloid negativity in patients with different stage mild cognitive impairment.
    He B; Wang L; Xu B; Zhang Y;
    Neurosci Lett; 2021 May; 754():135765. PubMed ID: 33667602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease.
    Grau-Rivera O; Navalpotro-Gomez I; Sánchez-Benavides G; Suárez-Calvet M; Milà-Alomà M; Arenaza-Urquijo EM; Salvadó G; Sala-Vila A; Shekari M; González-de-Echávarri JM; Minguillón C; Niñerola-Baizán A; Perissinotti A; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Gispert JD; Molinuevo JL;
    Alzheimers Res Ther; 2021 Feb; 13(1):46. PubMed ID: 33597012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral Markers of Vascular Endothelial Dysfunction Show Independent but Additive Relationships with Brain-Based Biomarkers in Association with Functional Impairment in Alzheimer's Disease.
    Drake JD; Chambers AB; Ott BR; Daiello LA;
    J Alzheimers Dis; 2021; 80(4):1553-1565. PubMed ID: 33720880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The recency ratio is related to CSF amyloid beta 1-42 levels in MCI-AD.
    Bruno D; Gleason CE; Koscik RL; Pomara N; Zetterberg H; Blennow K; Johnson SC
    Int J Geriatr Psychiatry; 2019 Mar; 34(3):415-419. PubMed ID: 30430632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline.
    Stockmann J; Verberk IMW; Timmesfeld N; Denz R; Budde B; Lange-Leifhelm J; Scheltens P; van der Flier WM; Nabers A; Teunissen CE; Gerwert K
    Alzheimers Res Ther; 2020 Dec; 12(1):169. PubMed ID: 33357241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.